Beyond Air, Inc. (XAIR) stock
Close on Nov 17, 2026Market cap $1.92MP/E –Yield –
Beyond Air, Inc. grew revenue 60.7% to $7.69M over the twelve months to Jun 30, 2026. Free cash flow was -$19.60M. At the latest close the market valued the company at $1.92M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.92M
- P/E ratio
- –
- Price to sales
- 0.25
- Price to book
- 0.96
- Dividend yield
- –
- Free cash flow yield
- -1018.22%
Fundamentals
- Revenue
- $7.69M
- Net income
- -$33.49M
- EPS, diluted
- -$68.58
- Free cash flow
- -$19.60M
- Book value per share
- $2.77
- Diluted shares
- 1M
Trading
- Next earnings
- Feb 12, 2027 (estimated, after the close)
- Previous close
- $2.02
- Open
- $2.03
- Day's range
- $1.94 – $2.04
- Volume
- 17,257
- Average volume (20 days)
- 66,773
- 52-week range
- $1.85 – $53.20
- RSI (14 days)
- 38.6
- Volatility (1 year)
- 181.8%
- Relative volume
- 0.10×
Market cap history
Month-end market cap since 2017, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.
| Period | XAIR | S&P 500 | Difference | XAIR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -6.9% | -4.0% | −2.9 pts | ||
| 3 months | -64.8% | -5.0% | −59.8 pts | ||
| Year to date | -86.2% | +8.2% | −94.4 pts | ||
| 1 year | -92.5% | +11.2% | −103.7 pts | ||
| 3 years | -99.7% | +68.5% | −168.1 pts | -85.0% | +19.0% |
| 5 years | -100.0% | +67.3% | −167.2 pts | -79.9% | +10.8% |
Ten years at a glance
Fiscal years 2015 to 2026 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Beyond Air filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- News
- Results
- News
About Beyond Air
Surgical & Medical Instruments & Apparatus
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company focused on developing and commercializing therapies utilizing nitric oxide (NO). The company's primary commercial offering is the LungFit PH system, an approved device designed to deliver therapeutic nitric oxide. In addition to commercializing this system, the organization explores novel therapeutic applications of nitric oxide through specialized subsidiaries, such as Beyond Cancer Ltd. and NeuroNos Ltd., which develop targeted product candidates categorized under pharmaceutical drug development.
Company profile, executives and historyBeyond Air stock: common questions
What is Beyond Air's stock price?
XAIR closed at $2.01 on Nov 17, 2026, down 0.50% on the day. Over the past 52 weeks it traded between $1.85 and $53.20.
What is Beyond Air's market cap?
Beyond Air was worth $1.92M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.
What is XAIR's P/E ratio?
Beyond Air lost money over the twelve months to Jun 30, 2026 (diluted EPS -$68.58), so it has no meaningful P/E ratio.
How much revenue does Beyond Air make?
Beyond Air reported revenue of $7.69M for the twelve months to Jun 30, 2026, up 60.7% from a year earlier.
Does Beyond Air pay a dividend?
No. Beyond Air has not paid a cash dividend over the last twelve months.
When does Beyond Air report earnings next?
Beyond Air is expected to report Q3 FY2027 results on Feb 12, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has XAIR stock performed over the past year?
Including dividends, XAIR returned -92.5% over the past year, against +11.2% for the S&P 500.
Who are Beyond Air's competitors?
Companies most similar to Beyond Air by business, industry and size include NSPR, MDNC, AURX, PMI, BDMD.
See a number that looks wrong?